pitavastatin calcium 4 MG Oral Tablet [Livalo]
pitavastatin calcium
RxCUI: 861654
What the CMS Formulary Data Shows for pitavastatin calcium 4 MG Oral Tablet [Livalo]
Per the CMS 2026 Part D formulary file, pitavastatin calcium 4 MG Oral Tablet [Livalo] (RxNorm concept RXCUI 861654, generic name pitavastatin calcium) appears on 11 distinct formulary files spanning 834 Medicare Part D plan offerings - 16.5% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 3 to Tier 3, with a cross-plan average of Tier 3.
Real-world access to pitavastatin calcium 4 MG Oral Tablet [Livalo] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 81.8% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 70,926 Part D beneficiaries filled pitavastatin calcium 4 MG Oral Tablet [Livalo] in 2023, with total plan-and-beneficiary spending of $189,914,605 and an average per-beneficiary annual cost of $2,677.64. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry pitavastatin calcium 4 MG Oral Tablet [Livalo] today.
Coverage Details
- Formularies covering
- 11
- Plans covering
- 834
- Coverage rate
- 16.5%
- Tier range
- Tier 3, Preferred Brand
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 81.8% of formularies
2023 Medicare Spending
- Beneficiaries
- 70,926
- Total spending
- $189,914,605
- Avg per beneficiary
- $2,677.64
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering pitavastatin calcium 4 MG Oral Tablet [Livalo]
2 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T3 | No | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T3 | No | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering pitavastatin calcium 4 MG Oral Tablet [Livalo]
98 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is pitavastatin calcium 4 MG Oral Tablet [Livalo] covered by Medicare Part D?
Yes, pitavastatin calcium 4 MG Oral Tablet [Livalo] is covered by 834 Medicare Part D plans (16.5% of all Part D formularies).
What tier is pitavastatin calcium 4 MG Oral Tablet [Livalo] on Medicare Part D plans?
pitavastatin calcium 4 MG Oral Tablet [Livalo] averages Tier 3 across Part D plans, ranging from Tier 3 to Tier 3.
Does pitavastatin calcium 4 MG Oral Tablet [Livalo] require prior authorization?
0% of Part D formularies require prior authorization for pitavastatin calcium 4 MG Oral Tablet [Livalo]. Step therapy: 0%. Quantity limits: 81.8%.
How much does Medicare spend on pitavastatin calcium 4 MG Oral Tablet [Livalo]?
In 2023, total Medicare Part D spending on pitavastatin calcium 4 MG Oral Tablet [Livalo] was $189,914,605, covering 70,926 beneficiaries. The average spend per beneficiary was $2,677.64.
Read our methodology - how this data is sourced, computed, and verified.